复旦张江(688505) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥299,076,861, representing a year-on-year increase of 14.77%[6] - The net profit attributable to shareholders for the same period was ¥53,128,822, a decrease of 4.73% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥47,320,806, showing a slight decrease of 0.56% year-on-year[6] - Total operating revenue for Q3 2021 reached 698,113,963, a 40.7% increase from 496,213,149 in the same period of 2020[40] - Net profit for Q3 2021 was 117,926,892, compared to 84,859,395 in Q3 2020, representing a 38.9% growth[42] - Earnings per share for Q3 2021 were 0.11, an increase from 0.09 in Q3 2020[45] - The company reported a total comprehensive income of 116,165,685 for Q3 2021, compared to 84,776,793 in Q3 2020, reflecting a 37.0% increase[45] Research and Development - The total R&D investment for Q3 2021 was ¥70,765,888, an increase of 41.05% compared to the same period last year[8] - R&D investment accounted for 23.66% of operating revenue in Q3 2021, an increase of 4.41 percentage points year-on-year[8] - Research and development expenses for Q3 2021 totaled 159,207,486, up from 102,365,503 in Q3 2020, indicating a 55.4% increase[40] - The company plans to invest a total of RMB 60,000,000 in the construction of a second-phase pharmaceutical production base to support future R&D projects[26] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥147,058,878, reflecting a significant increase of 662.49%[8] - Operating cash inflow for the first three quarters of 2021 reached RMB 775,540,672, a 40% increase from RMB 553,608,496 in the same period of 2020[48] - Cash and cash equivalents at the end of the period stood at RMB 919,497,196, down from RMB 1,416,742,573 at the end of the previous year[51] - The company reported a decrease in cash paid to employees to RMB 112,130,627 from RMB 119,862,895, reflecting a 6% reduction[48] - The net cash flow from financing activities was -RMB 88,889,372, a significant decrease from RMB 855,952,866 in the previous year[51] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,543,080,453, a 1.69% increase from the end of the previous year[8] - The equity attributable to shareholders at the end of the reporting period was ¥2,067,806,206, up 2.83% from the previous year[8] - The company's long-term equity investments increased significantly to RMB 321,918,991 from RMB 61,459,426, marking a growth of approximately 423.5%[30] - The total current assets decreased to RMB 1,739,117,480 from RMB 2,026,574,174, reflecting a reduction of about 14.2%[30] - Total liabilities decreased slightly to RMB 411,221,966 from RMB 427,925,821, a reduction of about 3.5%[34] Inventory and Shareholder Information - The company reported an increase in inventory to RMB 40,154,851 from RMB 36,009,341, which is an increase of approximately 11.9%[30] - The number of shareholders as of the reporting period was 21,993, with 21,842 holding A shares and 151 holding H shares[22] - The company granted 32.77 million restricted shares to 258 incentive recipients at a price of RMB 8.90 per share as part of its employee stock incentive plan[25]